TOI: Value-based oncology at scale — why the Elevance relationship matters

Thesis: The Oncology Institute (TOI) operates a hybrid oncology services and management business that monetizes through a mix of fee-for-service clinical care, dispensary drug sales, and value-based capitation/subscription contracts. TOI’s economic model is driven by shifting payor mixes—roughly half of revenue comes from value-based arrangements—and by its role as both a direct care operator and a management services organization for affiliated clinics. For investors evaluating customer relationships, the combination of capitated lives, dispensary margins, and MSAs that consolidate affiliated clinics creates differentiated revenue predictability and exposure to payor negotiation dynamics. Learn how we map these relationships at Null Exposure: https://nullexposure.com/

How TOI runs the business and where money flows

TOI runs three commercial segments: dispensary, patient services, and clinical trials & other, and it operates an integrated footprint of owned and affiliated clinics across multiple U.S. states. The company reported Revenue TTM of $424.4M and gross profit of $63.8M, while remaining unprofitable on the bottom line (reported diluted EPS TTM: -$0.67 and negative EBITDA). TOI’s revenue mix is a strategic axis: the company disclosed that 46% of 2024 revenue was generated from patients covered under value‑based contracts, and management has repeatedly emphasized the shift toward being a preferred or exclusive oncology group under those contracts.

Contracting posture is explicitly mixed:

Capitation / subscription-style contracts deliver population-level payments (often paid as fixed per-member-per-month or reconciled by performance) and are structurally longer-term; company materials note capitation contracts generally have legal terms of one year or longer.
Fee‑for‑service (FFS) work remains part of the model for physician services, infusion, radiation and other episodic care, and these FFS arrangements are typically short in duration (single-service periods).
TOI also operates management services agreements (MSAs) that make TOI Management the primary beneficiary for certain affiliated clinics, giving it operational control and a variable interest in those clinic economics.

These features create heterogeneous revenue durability: capitation and subscription payments increase predictability and align incentives for cost control, while dispensary and FFS provide margin upside tied to drug mixes and volume. The company monitors dispensary drug margins closely, which makes drug sourcing and formulary negotiation material to near-term operating leverage.

Contract counterparties and geographic footprint — concentrated, but diversified payor exposure

TOI takes payment from a range of counterparty types: commercial insurers, PBMs, Medicare (CMS), state Medicaid programs, other managed care organizations, and individual patients. The business is geographically focused in the U.S., operating clinics across five states and 16 markets, which concentrates operational risk regionally while still offering multi-state diversification. Company disclosures also highlight tax and regulatory exposure in California, Arizona, Florida, Oregon and Texas — states that represent material operational centers.

Collectively, these signals indicate a business with rising contractual maturity: management describes significant proportions of revenue as value-based and notes that more than half of the company’s revenue is derived from scenarios where payors designate TOI-affiliated providers as preferred or exclusive oncology groups, implying entrenched contracting relationships and higher switching costs for payors.

Customer relationship: Elevance Health — the Florida delegated capitated lives

TOI disclosed material progress on integration and MLR performance across the initial 40,000 delegated capitated lives under its partnership in Florida with Elevance Health. This is a population-level arrangement where TOI is responsible for fully delegated care for an assigned member base and receives capitated payments that shift risk and operational responsibility to the provider network. The disclosure came during a quarterly earnings call and was reported in an earnings transcript published March 10, 2026 by InsiderMonkey. (Source: InsiderMonkey, Q3 FY2025 earnings call transcript, March 10, 2026 — https://www.insidermonkey.com/blog/the-oncology-institute-inc-nasdaqtoi-q3-2025-earnings-call-transcript-1645573/)

Why that matters: a delegated, capitated relationship with a national payor like Elevance transforms revenue recognition and the company’s cost structure—capitation compresses revenue volatility but raises sensitivity to utilization management and care coordination effectiveness.

Explore structured customer relationship signals and research tools at Null Exposure: https://nullexposure.com/

How constraints shape investment risk and levers to monitor

Several company-level constraints and disclosures should define an investor’s monitoring checklist:

Contracting duration and posture: Capitation contracts are long-term (typically one year or longer), while FFS engagements are short and transactional. This creates a mixed balance between recurring revenue and episodic cash flow.
Materiality of value-based revenue: With about 46% of 2024 revenue coming from value-based contracts, TOI has meaningful exposure to payor performance metrics and risk-sharing arrangements; this is a primary driver of forward revenue stability.
Counterparty mix and regulatory exposure: Payments from government programs (Medicare and Medicaid) and PBMs are prominent; reimbursement policy shifts and state-level regulatory changes are high-impact levers for TOI’s top-line and margins.
Operational control via MSAs: TOI’s MSAs give management rights over affiliated TOI PCs and result in consolidation of those entities for accounting and operational decision-making, increasing the company’s ability to standardize care protocols and manage margins centrally.
Segment-level sensitivity: Dispensary economics are a critical margin lever; management regularly reviews drug margins, compression, and supplier relationships, which directly affects gross profit and cash flow.

Collectively, these constraints imply moderate contract concentration risk offset by durable, subscription‑like cash flows for a material portion of revenue, and a need to watch utilization, MLR performance, and dispensary margin trends as primary value drivers.

Investment implications — where upside and risk live

Upside drivers: scaling delegated capitations (like the Elevance tie), improving dispensary margins, and cross-selling management services to independent clinics will materially improve revenue visibility and operating leverage.
Key risks: negative EBITDA (-$40M TTM), operating losses, and sensitivity to payor reimbursement present downside; the company’s Price/Sales (~~0.67) and market cap (~~$288M) price the business as early-stage growth with operational risk.
Watch indicators: MLR trends, capitated lives growth, reconciliation outcomes on subscription contracts, and drug margin disclosures.

If you are building a watchlist for payor-dependent services companies or modeling value-based care cash flows, TOI’s customer relationships and the Elevance partnership are central inputs. For more signal-driven research and customer relationship mapping, see Null Exposure’s platform: https://nullexposure.com/

Closing CTA: For analysts and operators tracking customer-level exposure in healthcare, our coverage emphasizes contract type, criticality, and financial consequences—start your exploration at https://nullexposure.com/